Prevalence Rates of Personality Disorder and Its Association With Methamphetamine Dependence in Compulsory Treatment Facilities in China

Methamphetamine use is popular and rapidly increasing in China, and the co-occurrence of personality disorders has an impact on treatment outcomes and may increase vulnerability of developing dependence. The aim of the present study was to investigate the prevalence rates of personality disorders in methamphetamine users and further explore the association between personality disorders and methamphetamine use status. Five hundred and seventy-seven male methamphetamine users were recruited. The self-developed questionnaire was used for demographics, and a Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (SCID-I/II) was performed covering psychiatric diagnosis. Our study found the prevalence of antisocial personality disorder in male methamphetamine users was 71.4%, followed by borderline (20.2%) and obsessive-compulsive (17.9%) personality disorder. Borderline and antisocial personality disorders were found to be risk factors of methamphetamine dependence (adjusted odds ratio = 2.891, p = 0.007 and adjusted odds ratio = 1.680, p = 0.042). These findings suggested personality disorders were highly prevalent in male methamphetamine users, and the comorbidity of antisocial and borderline personality disorders are especially associated with methamphetamine dependence.

Introduction

Novel psychoactive substances (NPS) are synthetic substances that have been developed to produce altered states of consciousness and perceptions. The use of NPS has harmful outcomes on both physical and neuropsychiatric symptoms including respiratory depression, cardiac arrest or multiple organ failure (1). NPS users has higher risk of violence, assaultive, or aggressive behavior requiring restraint when compared with non-NPS users (2). Other symptoms of NPS include sedation and loss of consciousness, to bizarre repeated motions, to erratic running (3). As one of the most commonly known NPS (4), Methamphetamine (MA) has become the second-most prevalent used drug around the world (5). In China, the recreational use of MA is increasing and does not show signs of decreasing (5). In the year 2016, the MA-related seizures reached 29 tons and more than half of the newly reported drug users were MA users in China (6).

The poor treatment outcome and high relapse contributed to the prevalent abuse of MA (7). The comorbidity of personality disorders (PDs) negatively influenced the treatment of dependence (8) and relapse (9) in drug users including MA users (10). PDs are a class of mental disorders characterized by an enduring collection of behavioral patterns often associated with considerable personal, social and occupational disruption (11). Longitudinal studies showed that co-occurrence of PD in drug dependent users had impact on more problems (higher levels of crime, injection-related health problems), more severe drug use (overdose) and other psychiatric problem (major depression) (12, 13). Thus, better knowledge of PDs in MA users may help to improve the detoxification treatment and lower the relapse rate, and prevent the later negative outcomes of the comorbidity.

However, no epidemiologic survey has been reported on the comorbidity of PDs in a homogeneous group of methamphetamine users in the world. Previous studies showed high comorbidity of PD and substance use disorders (SUDs). The overall rates of PD among patients with SUD ranged from 50 to 92% (14). Unfortunately, these data on PDs prevalence in SUD population were not well-applicable to MA users. Personality profiles were reported to link the preferential choice of drugs (15), which indicating different prevalence rates of PDs in different types of drug users. It is also supported by another 1-year longitudinal study, which found that MA users were significantly different from alcohol and marijuana users on PD related factors (16), such as the respect to completion of and readmission to treatment, employment and various forms of criminal justice involvement (17).

The dependence on MA was one of the main reasons for high relapse in MA users (18). As a strong central nervous system (CNS) stimulant, MA is known to have a high dependence liability. MA dependence is a chronic relapsing disorder characterized by compulsive MA use, loss of control over intake, and impairment in social and occupational function (19). PD increased the possibility for developing dependence in drug users (20, 21). However, no studies reported the association between MA dependence and PDs.

Therefore, our study tried to investigate the prevalent rates of PDs in MA users and further explore the association between PD and MA dependence. Our study may provide evidence of the PD prevalence in MA users in compulsory detoxification facilities in China. The association between PD and the dependence of MA may help to offer evidence for the development from MA use to dependence.

Methods

Participants and Design

The 577 participants in this study were from two male compulsory detoxification treatment facilities (including Xinkaipu and Bainihu) from July 2013 to November 2013 in Hunan province, China. Compulsory rehabilitation is the primary form of treatment for illegal drug dependence in China (61.6% drug users received compulsory treatment by 2012) (22). The residential MA users were admitted in the treatment facilities after confirmed MA use by urine or hair test. Routine physical exams were performed before the admission. There were 52 MA users (9.0%) excluded because of uncompleted data. In the end, 525 MA users remained in the study. Inclusion criteria of MA users were as follows: age ≥18 years old, admitted compulsively because of MA use; mainly used MA and did not use heroin at least 1 year before admission, and able to give consent. Those MA users with current psychotic symptoms were interviewed after these symptoms disappeared. The exclusion criteria were as follows: having severe somatic disorders and any history of severe brain diseases, such as brain trauma, epilepsy, or encephalitis. To explore the association, the MA users were then divided based on the results of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis into two groups: MA-dependent and non-dependent users. All subjects expressed a wish to participate in the study in order to receive medical examinations from the psychiatrists conducting the investigation, out of concern for their own health. They were free to abstain from participation in the study or to withdraw from it without threat of punishment. All the participants freely gave informed consent prior to their inclusion in the study. The research protocol and informed consent were approved by the Human Ethics Committee of the Second Xiangya Hospital of Central South University.

Procedure

Sociodemographic data were collected initially. Then, face-to-face interviews were conducted by three trained psychiatrists. Structured Clinical Interviews for DSM-IV Axis I disorders and personality disorders (SCID-I/II), Chinese version (23) were used for the diagnoses; there was a good inter-rater reliability of (kappa = 1.0) among the three psychiatrists. Approximately 1.5–2 h were utilized for the whole interview.

Statistical Analyses

All the statistical analyses were entered into SPSS (version 22.0) for Windows. Means and frequencies were computed. Group comparisons were performed between MA-dependent and non-dependent users using Independent t-test, Chi-square test and Fisher exact test as appropriate. The association between each PD and MA dependence was evaluated where there were significant group differences between PDs. Relationships between factors and one binary outcome variables (MA-dependent and non-dependent users) were tested with multiple logistic regression models, controlling for demographics (age), Axis I disorders (psychotic disorder, dependence of hypnotics/heroin/ketamine) and MA use pattern (onset age of MA use, duration of MA use and routes of MA administration). Each multiple logistic regression model produced adjusted odds ratios and 95% confidence intervals for the PD. The level of significance was set at 0.05 in all analyses.

Results

Five hundred and twenty-five male MA users were analyzed in the study. Table 1 showed the sociodemographic data and lifetime diagnoses of Axis I disorders of the study sample and the differences between the two subgroups. The MA users suffered from affective disorder (26.1%), followed by psychotic disorder (20.2%), and anxiety disorder (7.2%). Alcohol dependence was diagnosed in 17.5% MA users. MA users also used other drugs and were diagnosed with a lifetime dependence, such as heroin (34.1%), hypnotics (9.1%), ketamine (8.2%), cannabis (1.5%), and cocaine (0.4%). The MA use pattern was shown in Table 2. The average age of the first MA use was 23.3 years old. The mean duration of MA use was 32.6 months among all MA users. Most of the MA users (74.5%) used MA by smoking. The prevalence rate of PD among male MA users was highest for antisocial (71.4%), followed by borderline (20.2%), obsessive-compulsive (17.9%), avoidant (16.2%), paranoid (14.3%), negativistic (14.1%), narcissistic (6.3%), histrionic (5.5%), schizoid (5.1%), dependent (1.5%), and schizotypal (0.6%) PDs (Table 3).

TABLE 1

Table 1. Demographic and clinical data of the study sample.

TABLE 2

Table 2. Methamphetamine (MA) use pattern of the study sample and group comparison between MA-dependent and non-dependent users.

TABLE 3

Table 3. Prevalence rates of personality disorders (PDs) of the study sample and group comparison between methamphetamine (MA)-dependent and non-dependent users.

Among all the MA users, 73.9% of MA users were diagnosed with MA dependence. The MA-dependent users were older than MA non-dependent users (mean age = 33.7 vs. 31.8, p = 0.006). There were no significant differences in marriage and education levels between the two groups. Significantly more MA-dependent users were diagnosed with a past psychotic disorder (22.7 vs. 13.1%, p = 0.017) and dependences of hypnotics (11.3 vs. 2.9%, p = 0.003), heroin (37.6 vs. 24.1%, p = 0.004), and ketamine (10.3 vs. 2.2%, p = 0.003). No other significant differences were found for the diagnoses of Axis I disorders. A younger onset age of MA use was observed in MA-dependent users compared with those in the MA non-dependent user group (mean age = 22.8 vs. 24.9, p = 0.001). MA-dependent users had markedly longer duration of MA use than MA non-dependent users (35.4 vs. 24.6 months, p < 0.001). In addition, there were significant differences of routes of administration (p < 0.001) between the two groups (MA-dependent and non-dependent users). The different diagnoses rates of PDs between MA-dependent users and MA non-dependent users were presented in Figure 1. There were significant group differences of three PDs, which included schizoid (p = 0.002), borderline (p = 0.001) and antisocial (p < 0.001) PD. The results of the multiple logistic regression model analyses were shown in Table 4, testing the associations of the three PDs with MA dependence after controlled for age, diagnoses of a past psychotic disorder, dependences of hypnotics/heroin/ketamine, age of first MA use, duration of MA use (months) and routes of MA administration. Borderline and antisocial PDs were both risk factors for MA dependence.

FIGURE 1

Figure 1. Prevalence rates of personality disorders (PDs) between methamphetamine (MA)-dependent users and non-dependent users.

TABLE 4

Table 4. Multivariate logistic regression models to estimate the association between each personality disorder (PD) and methamphetamine (MA) dependence.

Discussion

Prevalent Rates of Personality Disorders in MA Users

Our study showed much higher prevalence rates of PDs among male MA users than general population (24, 25), schizophrenia patients (26), and female prison inmates (27). The rank of the PDs' prevalence in male MA-dependent users was consistent with a report for male heroin-dependent users in the same setting in China (28). The present study showed relatively higher rates of PDs when compared with Yang's study (28), such as antisocial PD (75.5 vs. 54.2%), borderline PD (23.7 vs. 22.7%), avoidant PD (17.3 vs. 13.9%), paranoid PD (15.7 vs. 8.5%), and negativistic PD (14.9 vs. 11.9%). These differences of PD rates could be mainly due to the different populations (MA vs. heroin). In a study of depressed patient with and without borderline PD, genetic association was found between dopamine transporter (DAT1) and borderline PD (29). Another study found serotonin receptor gene (5-HTT) was associated with BPD gene among BPD patients and healthy controls (30). Antisocial PD was also found associations with dopamine and serotonin transporter genes in alcoholics (31). Thus, borderline or antisocial PD was related to dopamine and serotonin transporters. MA had adverse effects on dopaminergic and serotonin neurons (32) related to PD while heroin affected the opioid receptor (33). Second, the personality trait scores related to the PDs were higher in CNS simulant users (including MA) than those in opioid users (34), which suggested more personality problems for MA users. Third, if use of drug induced PD chronically, then the diagnosis of PD may make a difference at different stages during the clinical course of drug use. Therefore, different clinical courses may also influence the differentiation of PD rates between MA and heroin users. Fourth, the presence of Axis I disorders can influence the prevalence rates of PD including depression (35) and anxiety disorder (36), which were different between our study and Yang's study (28).

Association Between Personality Disorder and Methamphetamine Dependence

The high prevalence rates of PDs suggested a relationship with MA use. After adjusted with confounding factors, borderline and antisocial PDs were found to be associated risk factors for MA dependence, which were consistently found in patients with substance dependence (37), heroin use (38), and alcohol dependence (39). There were several reasons for the associations between borderline/antisocial PD and MA dependence. First, as a core feature of borderline/antisocial PD, the emotional dysregulation induced more severity of MA use (21). In the present study, MA-dependent users were younger with younger age of first MA use, and they had markedly longer duration of MA use, logically suggested heavier use of MA than MA-non-dependent users. With the repeated severe use of MA, the MA users with borderline/antisocial PD gradually developed to MA dependence. Second, prefrontal cortex (PFC) may play a role in the associations between borderline, antisocial PD and MA dependence. Previous studies showed reduction of gray matter volume in PFC among individuals with borderline PD (40) and antisocial PD (41) when compared with healthy subjects. Prefrontal dysfunction was also found in MA dependent subjects (42). And another study showed that MA-dependent smokers had smaller gray matter volume in the PFC when compared with control non-smokers (43). Thus, PD and the dependence of MA came together to damage the brain region of PFC. In turn, PFC dysfunction induced dysregulation of limbic reward regions (related to addiction) and impairment of higher-order executive function including self-control, salience attribution and awareness (related to PD) (44). MA users with executive dysfunction (45) would also increase the chance to have more severe drug use and became a dependent user easily.

Possible Role of Personality Disorder During the Development of Methamphetamine Dependence

As a cross-sectional study, the present study cannot clarify the causality between the PDs and MA dependence. There has been reported in a longitudinal study, that the antisocial PD was associated with the later drug dependence at 5 years follow-up (46). In our study, MA-dependent users showed longer duration of MA use than those without dependence, indicating the clinical course of development from MA use to dependence. Therefore, we tried to interpret the role of borderline/antisocial PD during the clinical course of MA use. The first possible reason was borderline/antisocial PD accelerated the clinical course from MA use to dependence. High compulsivity may mediate the transformation from the use to the dependence of MA. As the common feature of borderline and antisocial PDs (47), high compulsivity was also the core feature of dependence (48). The possible pathway was that patients with borderline or antisocial PD has high impulsivity which increased the risk of MA use. Then the chronic use of MA would in turn have impact on borderline or antisocial PD and caused higher impulsivity. The long-term interaction effect of MA use and PD finally induced MA dependence. High impulsivity was found in patients with borderline (49) and antisocial PD (50). Those borderline or antisocial PD patients were susceptible population of MA use (51, 52). MA had neurotoxic effects on human serotonin neurons (53), so did for borderline PD (30) and antisocial PD (31). With chronic use of MA, the MA users with borderline or antisocial PD suffered serotonin deficiencies and had higher impulsivity (54) by genetic vulnerability (55). The dependence of MA finally occurred following the co-occurrence of borderline or antisocial PD in chronic MA users. The other possibility was the MA dependence and borderline/antisocial PD appeared simultaneously with common pathway. In a study of marijuana-dependent users, the comorbidity of antisocial PD and MA dependence was found to increase each other by genetic effect (56). The genetic susceptibility was found between MA dependence and PD mediated by the neuronal cell adhesion molecule (NrCAM) gene variants (57). In addition, dopamine might play a role in the comorbidity of MA dependence and PD (58). A positron emission tomography (PET) study found dopamine increase in PD with addiction group when compared with PD without medication addiction group on the response to a single dose of levodopa (59), suggesting the interaction between addiction and PD.

Our study suggested specific assessment for personality to reduce the possibility from MA use to dependence. For example, Temperament and Character Inventory (TCI) (60) was used in drug dependent users for personality assessment (61). This tool can help elucidate which addiction-associated personality variables are embedded.

There is a need to develop researchers in the area of MA dependence treatment. First, 12-step could be considered as a rehabilitation strategy. A study found that this strategy could provide low- or no-cost options for MA users and increase the capacity for providing treatment (62). Moreover, research showed that the 12-step recovery could be better used for young drug dependent users (63). Our study showed that the onset age of MA use was about 23 years old and their average age was 33 years old. For pharmacotherapy, lisdexamfetamine (LiMA) was recommended for the potential MA dependence treatment (64). Except for the above, Repetitive transcranial magnetic stimulation (rTMS) was also a potential treatment for the MA dependence. The rTMS can directly target and remodel dysfunctions in brain circuits including reward processing, craving, inhibitory and cognitive control, mood, and learning. A pilot study showed that rTMS could help treat the symptom of anhedonia and craving in cocaine users (65).

We have several limitations in our study. First, this is a cross-sectional study that cannot interpret the causality between MA dependence and PD. Second, only male MA users were recruited. The gender effect cannot be detected. Third, the MA users also co-abused other drugs. The impact of other drug use on MA users may exist, even controlled dependences of other drugs.

In conclusion, the comorbidity of PDs in male MA users was prevalent in compulsory detoxification facilities in China. The screening of PDs would be warranted in MA users during admission of detoxification treatment. Most MA users were dependent users in compulsory detoxification facilities in China. Borderline and antisocial PDs were risk factors for MA dependence. The individualized treatment of MA use was suggested with comorbid PD to achieve better treatment outcome and lower relapse rate. The treatment of borderline and antisocial PDs can help to decrease or even prevent dependence of MA.

Author Contributions

WH conceived and designed this study. CZ, LL, and HD collected the data. CZ conceived and conducted statistical analyses, with additional advice regarding analyses contributed by TL. CZ drafted the manuscript which was approved by all authors.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors wish to thank the staff at the two male compulsory detoxification treatment facilities for their assistance.

References

1. Assi S, Gulyamova N, Ibrahim K, Kneller P, Osselton D. Profile, effects, and toxicity of novel psychoactive substances: a systematic review of quantitative studies. Hum Psychopharm Clin. (2017) 32:e2607. doi: 10.1002/hup.2607

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Shafi A, Gallagher P, Stewart N, Martinotti G, Corazza O. The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services. Hum Psychopharm Clin. (2017) 32:21–9. doi: 10.1002/hup.2606

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Gray R, Bressington D, Hughes E, Ivanecka A. A systematic review of the effects of novel psychoactive substances ‘legal highs' on people with severe mental illness. J Psychiatr Ment Health Nurs. (2016) 23:267–81. doi: 10.1111/jpm.12297

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, et al. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharm Clin. (2015) 30:295–301. doi: 10.1002/hup.2486

PubMed Abstract | CrossRef Full Text | Google Scholar

5. United Nations Office on Drugs and Crime. World Drug Report 2016. New York, NY: UNODC (2016).

6. National Narcotics Control Commission. Annual Report on Drug Control in China. Beijing: China National Narcotics Control Commission (2017).

7. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat. (2003) 24:267–77. doi: 10.1016/s0740–5472(03)00028-x

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Arndt I, Mclellan AT, Dorozynsky L, Woody GE, O'brien CP. Desipramine treatment for cocaine dependence: role of antisocial personality disorder. J Nerv Ment Dis. (1994) 182:151–6. doi: 10.1097/00005053–199403000–00004

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Leal J, Ziedonis D, Kosten T. The prognostic significance of antisocial personality disorder in the treatment of cocaine dependence using pharmacotherapy. NIDA Res Monogr. (1994) 141:434.

Google Scholar

10. Fletcher JB, Reback CJ. Antisocial personality disorder predicts methamphetamine treatment outcomes in homeless, substance-dependent men who have sex with men. J Subst Abuse Treat. (2013) 45:266–72. doi: 10.1016/j.jsat.2013.03.002

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Millon T, Davis RO. Disorders of Personality: DSM-IV and Beyond. New York, NY: John Wiley & Sons (1996).

Google Scholar

12. Darke S, Ross J, Williamson A, Mills KL, Havard A, Teesson M. Borderline personality disorder and persistently elevated levels of risk in 36-month outcomes for the treatment of heroin dependence. Addiction (2007) 102:1140–6. doi: 10.1111/j.1360–0443.2007.01876.x

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Darke S, Ross J, Williamson A, Teesson M. The impact of borderline personality disorder on 12-month outcomes for the treatment of heroin dependence. Addiction (2005) 100:1121–30. doi: 10.1111/j.1360–0443.2005.01123.x

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Sher KJ, Trull TJ. Substance use disorder and personality disorder. Curr Psychiatr Rep. (2002) 4:25–9. doi: 10.1007/s11920-002-0008-7

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Gerra G, Bertacca S, Zaimovic A, Pirani M, Branchi B, Ferri M. Relationship of personality traits and drug of choice by cocaine addicts and heroin addicts. Subst Use Misuse (2008) 43:317–30. doi: 10.1080/10826080701202726

PubMed Abstract | CrossRef Full Text | Google Scholar

16. McMahon RC, Enders C. Personality disorder factors predict recovery of employment functioning among treated cocaine abusers. Am J Drug Alcohol Abuse (2009) 35:138–44. doi: 10.1080/00952990902825397

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Luchansky B, Krupski A, Stark K. Treatment response by primary drug of abuse: does methamphetamine make a difference? J Subst Abuse Treat. (2007) 32:89–96. doi: 10.1016/j.jsat.2006.06.007

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. (2001) 63:269–76. doi: 10.1016/s0376–8716(00)00217–9

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatr. (2008) 20:145–55. doi: 10.1080/10401230802177656

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Leal J, Ziedonis D, Kosten T. Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence. Drug Alcohol Depend. (1994) 35:31–5. doi: 10.1016/0376–8716(94)90107–4

PubMed Abstract | CrossRef Full Text

21. Verheul R. Co-morbidity of personality disorders in individuals with substance use disorders. Eur Psychiatr. (2001) 16:274–82. doi: 10.1016/s0924–9338(01)00578–8

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Zhong B, Xiang Y, Cao X, Li Y, Zhu J, Chiu HF. Prevalence of antisocial personality disorder among Chinese individuals receiving treatment for heroin dependence: a meta-analysis. Shanghai Arch Psychiatr. (2014) 26:259–71. doi: 10.11919/j.issn.1002-0829.214091

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey. Lancet (2009) 373(9680):2041–53. doi: 10.1016/s0140–6736(09)60660–7

CrossRef Full Text | Google Scholar

24. Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatr. (2006) 188:423–31. doi: 10.1192/bjp.188.5.423

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatr. (2008) 69:533. doi: 10.4088/jcp.v69n0404

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Wei Y, Zhang T, Chow A, Tang Y, Xu L, Dai Y, et al. Co-morbidity of personality disorder in schizophrenia among psychiatric outpatients in China: data from epidemiologic survey in a clinical population. BMC Psychiatr. (2016) 16:224. doi: 10.1186/s12888–016–0920–8

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Zhu XM, Zhou JS, Chen C, Peng WL, Li W, Ungvari GS, et al. Prevalence of borderline personality disorder and its risk factors in female prison inmates in China. Psychiatr Res. (2017) 250:200–3. doi: 10.1016/j.psychres.2017.01.065

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Yang M, Mamy J, Zhou L, Liao YH, Wang Q, Seewoobudul V, et al. Gender differences in prevalence and correlates of antisocial personality disorder among heroin dependent users in compulsory isolation treatment in China. Addict Behav. (2014) 39:573–9. doi: 10.1016/j.addbeh.2013.11.003

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Joyce PR, McHugh PC, McKenzie JM, Sullivan PF, Mulder RT, Luty SE, et al. A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients. Psychol Med. (2006) 36:807–13. doi: 10.1017/s0033291706007288

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Ni X, Chan K, Bulgin N, Sicard T, Bismil R, McMain S, et al. Association between serotonin transporter gene and borderline personality disorder. J Psychiatr Res. (2006) 40:448–53. doi: 10.1016/j.jpsychires.2006.03.010

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Reese J, Kraschewski A, Anghelescu I, Winterer G, Schmidt LG, Gallinat J, et al. Haplotypes of dopamine and serotonin transporter genes are associated with antisocial personality disorder in alcoholics. Psychiatr Genet. (2010) 20:140–52. doi: 10.1097/ypg.0b013e32833a1ecb

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, Hata H, et al. Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol. (2007) 572:120–8. doi: 10.1016/j.ejphar.2007.06.022

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Tan EC, Tan CH, Karupathivan U, Yap EP. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport (2003) 14:569–72. doi: 10.1097/00001756–200303240–00008

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Valila J. The Relationship Between Personality Type and Drug of Choice Among Substance Users. Dissertation/PhD's thesis. Walden University (2008).

Google Scholar

35. Rothschild L, Zimmerman M. Interface between personality and depression. In: Alpert JE, Fava M, editors. Handbook of Chronic Depression: Diagnosis and Therapeutic Management. New York, NY: CRC Press Inc (2003). p. 19.

Google Scholar

36. Gratz KL, Tull MT, Gunderson JG. Preliminary data on the relationship between anxiety sensitivity and borderline personality disorder: the role of experiential avoidance. J Psychiatr Res. (2008) 42:550–9. doi: 10.1016/j.jpsychires.2007.05.011

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Freestone M, Howard R, Coid JW, Ullrich S. Adult antisocial syndrome co-morbid with borderline personality disorder is associated with severe conduct disorder, substance dependence and violent antisociality. Personal Ment Health (2013) 7:11–21. doi: 10.1002/pmh.1203

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Darke S, Williamson A, Ross J, Teesson M, Lynskey M. Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend. (2004) 74:77–83. doi: 10.1016/j.drugalcdep.2003.12.002

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Ayers WA. Taxometric Analysis of Borderline and Antisocial Personality Disorders in a Drug and Alcohol Dependent Population. New York, NY: Diss. ProQuest Information & Learning (2000).

Google Scholar

40. O'Neill A, D'Souza A, Carballedo A, Joseph S, Kerskens C, Frodl T. Magnetic resonance imaging in patients with borderline personality disorder: a study of volumetric abnormalities. Psychiatr Res. (2013) 213:1–10. doi: 10.1016/j.pscychresns.2013.02.006

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Liu H, Liao J, Jiang W, Wang W. Changes in low-frequency fluctuations in patients with antisocial personality disorder revealed by resting-state functional MRI. PLoS ONE (2014) 9:e89790. doi: 10.1371/journal.pone.0089790

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, et al. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology (2002) 26:53–63. doi: 10.1016/s0893–133x(01)00334–7

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Morales AM, Lee B, Hellemann G, O'Neill J, London ED. Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine. Drug Alcohol Depend. (2012) 125:230–8. doi: 10.1016/j.drugalcdep.2012.02.017

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. (2011) 12:652–69. doi: 10.1038/nrn3119

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Moon M, Do KS, Park J, Kim D. Memory impairment in methamphetamine dependent patients. Int J Neurosci. (2007) 117:1–9. doi: 10.1080/00207450500535503

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Fridell M, Hesse M, Johnson E. High prognostic specificity of antisocial personality disorder in patients with drug dependence: results from a five-year follow-up. Am J Addict. (2006) 15:227–32. doi: 10.1080/10550490600626440

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Hollander E, Rosen J. Impulsivity. J Psychopharmacol. (2000) 14(2 Suppl. 1):S39–44. doi: 10.1177/02698811000142s106

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Davis C, Carter JC. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite (2009) 53:1–8. doi: 10.1016/j.appet.2009.05.018

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Soloff PH, Chiappetta L, Mason NS, Becker C, Price JC. Effects of serotonin-2A receptor binding and gender on personality traits and suicidal behavior in borderline personality disorder. Psychiatr Res. (2014) 222:140–8. doi: 10.1016/j.pscychresns.2014.03.008

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Moeller FG, Dougherty DM, Barratt ES, Oderinde V, Mathias CW, Harper RA, et al. Increased impulsivity in cocaine dependent subjects independent of antisocial personality disorder and aggression. Drug Alcohol Depend. (2002) 68:105–11. doi: 10.1016/s0376–8716(02)00106–0

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Trull TJ, Sher KJ, Minks-Brown C, Durbin J, Burr R. Borderline personality disorder and substance use disorders: a review and integration. Clin Psychol Rev. (2000) 20:235–53. doi: 10.1016/S0272–7358(99)00028–8

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Grande TP, Wolf AW, Schubert DS, Patterson MB, Brocco K. Associations among alcoholism, drug abuse, and antisocial personality: a review of literature. Psychol Rep. (1984) 55:455–74.

PubMed Abstract | Google Scholar

53. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. (2009) 60:379–407. doi: 10.1016/j.brainresrev.2009.03.002

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Semple SJ, Zians J, Grant I, Patterson TL. Impulsivity and methamphetamine use. J Subst Abuse (2005) 29:85–93. doi: 10.1016/j.jsat.2005.05.001

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Nomura M, Kusumi I, Kaneko M, Masui T, Daiguji M, Ueno T, et al. Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. Psychopharmacology (2006) 187:30–5. doi: 10.1007/s00213–006–0398-z

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Fu Q, Heath AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, et al. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men. Arch Gen Psychiatr. (2002) 59:1125–32. doi: 10.1001/archpsyc.59.12.1125

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Yoo BK, Shim JC, Lee BD, Kim C, Chung YI, Park JM, et al. Association of the neuronal cell adhesion molecule (NrCAM) gene variants with personality traits and addictive symptoms in methamphetamine use disorder. Psychiatr Investig. (2012) 9:400–7. doi: 10.4306/pi.2012.9.4.400

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron (2009) 61:502–10. doi: 10.1016/j.neuron.2009.01.031

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. (2006) 59:852–8. doi: 10.1002/ana.20822

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Martinotti G, Cloninger C, Janiri L. Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. Am J Drug Alcohol Abuse (2008) 34:177–83. doi: 10.1080/00952990701877078

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Le Bon O, Basiaux P, Streel E, Tecco J, Hanak C, Hansenne M, et al. Personality profile and drug of choice; a multivariate analysis using Cloninger's TCI on heroin addicts, alcoholics, and a random population group. Drug Alcohol Depend. (2004) 73:175–82. doi: 10.1016/j.drugalcdep.2003.10.006

CrossRef Full Text | Google Scholar

62. Donovan DM, Wells EA. ‘Tweaking 12-Step': the potential role of 12-Step self-help group involvement in methamphetamine recovery. Addiction (2007) 102:121–9. doi: 10.1111/j.1360-0443.2007.01773.x

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Garrett SB, Doyle SR, Peavy KM, Wells EA, Owens MD, Shores-Wilson K, et al. Age differences in outcomes among patients in the “Stimulant Abuser Groups to Engage in 12-Step”(STAGE-12) intervention. J Subst Abuse Treat. (2018) 84:21–9. doi: 10.1016/j.jsat.2017.10.012

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Ezard N, Dunlop A, Hall M, Ali R, McKetin R, Bruno R, et al. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open (2018) 8:e020723. doi: 10.1136/bmjopen-2017–020723

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Pettorruso M, Spagnolo PA, Leggio L, Janiri L, Di Giannantonio M, Gallimberti L, et al. Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder: a pilot study. Brain Stimul. (2018) 11:1195–7. doi: 10.1016/j.brs.2018.06.001

PubMed Abstract | CrossRef Full Text | Google Scholar